{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:06:10Z","timestamp":1793419570487,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01 AA027760"],"award-info":[{"award-number":["R01 AA027760"]}]},{"name":"NIH","award":["R01 AA026589"],"award-info":[{"award-number":["R01 AA026589"]}]},{"name":"NIH","award":["R21 AA027614"],"award-info":[{"award-number":["R21 AA027614"]}]},{"name":"NIH","award":["P20 GM130414"],"award-info":[{"award-number":["P20 GM130414"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00213-024-06598-6","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:02:46Z","timestamp":1714370566000},"page":"1101-1110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials"],"prefix":"10.1007","volume":"241","author":[{"given":"Paul S.","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallece E.","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-5679","authenticated-orcid":false,"given":"Carolina L.","family":"Haass-Koffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"6598_CR1","unstructured":"American Psychiatric Association A, Association AP (1994) Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association, Washington, DC"},{"key":"6598_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O\u2019donnell K, Owens IT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 79:953\u2013962","journal-title":"JAMA Psychiatry"},{"key":"6598_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41591-021-01524-1","volume":"27","author":"MJ Burke","year":"2021","unstructured":"Burke MJ, Blumberger DM (2021) Caution at psychiatry\u2019s psychedelic frontier. Nat Med 27:1687\u20131688","journal-title":"Nat Med"},{"key":"6598_CR4","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler M, Jelen L, Rucker J (2022) Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology 239:3047\u20133055","journal-title":"Psychopharmacology"},{"key":"6598_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-harriS","year":"2021","unstructured":"Carhart-harriS R, Giribaldi B, Watts R, Baker-jones M, Murphy-beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 384:1402\u20131411","journal-title":"N Engl J Med"},{"key":"6598_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","volume":"12","author":"F Cavanna","year":"2022","unstructured":"Cavanna F, Muller S, De La Fuente LA, Zamberlan F, Palmucci M, Janeckova L, Kuchar M, Pallavicini C, Tagliazucchi E (2022) Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry 12:307","journal-title":"Transl Psychiatry"},{"key":"6598_CR7","doi-asserted-by":"publisher","first-page":"116715","DOI":"10.1016\/j.jns.2020.116715","volume":"411","author":"T Chi","year":"2020","unstructured":"Chi T, Gold JA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci 411:116715","journal-title":"J Neurol Sci"},{"key":"6598_CR8","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, Yazar-klosinski B, Emerson A (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235:3137\u20133148","journal-title":"Psychopharmacology"},{"key":"6598_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/JCP.0000000000001428","volume":"41","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, Osorio FL, RochA JM, Rossi GN, Bouso JC, Rodrigues LS, De OliveirASilveira G, Yonamine M, Hallak JEC (2021) Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol 41:540\u2013550","journal-title":"J Clin Psychopharmacol"},{"key":"6598_CR10","doi-asserted-by":"publisher","first-page":"e2019686","DOI":"10.1001\/jamanetworkopen.2020.19686","volume":"3","author":"CK Ettman","year":"2020","unstructured":"Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S (2020) Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open 3:e2019686","journal-title":"JAMA Netw Open"},{"key":"6598_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513\u2013520","journal-title":"J Nerv Ment Dis"},{"key":"6598_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-coker K, Carhart-harris R, Cattell J, Daniel A, Debattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-keller JL, Mars J, Marwood L, Mcelhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O\u2019keane V, Palenicek T, Printz D, Rademaker MC, Vanreemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med 387:1637\u20131648","journal-title":"N Engl J Med"},{"key":"6598_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, Mccann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268\u201383 (discussion 284-92)","journal-title":"Psychopharmacology (Berl)"},{"key":"6598_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30:1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"6598_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, Mckay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71\u201378","journal-title":"Arch Gen Psychiatry"},{"key":"6598_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/02698811231200880","volume":"37","author":"BJ Gully","year":"2023","unstructured":"Gully BJ, Eaton E, Capone C, Haass-koffler CL (2023) Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy. J Psychopharmacol 37:1182\u20131189","journal-title":"J Psychopharmacol"},{"key":"6598_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME (2023) Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry 93:215\u2013223","journal-title":"Biol Psychiatry"},{"key":"6598_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13293-020-00288-6","volume":"11","author":"GS Kim","year":"2020","unstructured":"Kim GS, Uddin M (2020) Sex-specific and shared expression profiles of vulnerability and resilience to trauma in brain and blood. Biol Sex Differ 11:13","journal-title":"Biol Sex Differ"},{"key":"6598_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","volume":"322","author":"K Ko","year":"2023","unstructured":"Ko K, Kopra EI, Cleare AJ, Rucker JJ (2023) Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. J Affect Disord 322:194\u2013204","journal-title":"J Affect Disord"},{"key":"6598_CR20","doi-asserted-by":"publisher","first-page":"204512532095056","DOI":"10.1177\/2045125320950567","volume":"10","author":"KPC Kuypers","year":"2020","unstructured":"Kuypers KPC (2020) The therapeutic potential of microdosing psychedelics in depression. Ther Adv Psychopharmacol 10:2045125320950567","journal-title":"Ther Adv Psychopharmacol"},{"key":"6598_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","volume":"33","author":"KP Kuypers","year":"2019","unstructured":"Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol 33:1039\u20131057","journal-title":"J Psychopharmacol"},{"key":"6598_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/wps.20941","volume":"21","author":"F Leichsenring","year":"2022","unstructured":"Leichsenring F, Steinert C, Rabung S, Ioannidis JPA (2022) The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry 21:133\u2013145","journal-title":"World Psychiatry"},{"key":"6598_CR23","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"6598_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","volume":"52","author":"JB Luoma","year":"2020","unstructured":"Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R (2020) A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs 52:289\u2013299","journal-title":"J Psychoactive Drugs"},{"key":"6598_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, BogenschutZ M, Lilienstein A, Harrison C, Kleiman S, Parker-guilbert K, Ot\u2019alora GM, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, Van Der Kolk B, TzarfatY K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, HamiltoN S, Wang JB, Coker A, Matthews R, De Boer A, Yazar-klosinski B, Emerson A, Doblin R (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27:1025\u20131033","journal-title":"Nat Med"},{"key":"6598_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439\u2013452","journal-title":"J Psychopharmacol"},{"key":"6598_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, MithoefeR AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-klosinski B, Emerson A, Doblin R (2018) 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486\u2013497","journal-title":"Lancet Psychiatry"},{"key":"6598_CR28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735\u20131740","journal-title":"J Clin Psychiatry"},{"key":"6598_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 14:1133\u20131152","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6598_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (+\/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol 27:40\u201352","journal-title":"J Psychopharmacol"},{"key":"6598_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Ot'alora","year":"2018","unstructured":"Ot\u2019alora GM, Grigsby J, Poulter B, Van Derveer JW III, Giron SG, Jerome L, Feduccia AA, Hamilton S, Yazar-klosinski B, Emerson A, Mithoefer MC, Doblin R (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. J Psychopharmacol 32:1295\u20131307","journal-title":"J Psychopharmacol"},{"key":"6598_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-fontes","year":"2019","unstructured":"Palhano-fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-rolim SA, Os\u00f3rio FL, Sanches R, Dos santos RG, T\u00f3foli LF, De Oliveira Silveira G, Yonamine M, RibA J, Santos FR, Silva-junior AA, Alchieri JC, Galv\u00e3o-coelho NL, Lob\u00e3o-soares B, Hallak JEC, Arcoverde E, Maia-de-oliveira JP, Ara\u00fajo DB (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49:655\u2013663","journal-title":"Psychol Med"},{"key":"6598_CR33","unstructured":"Pull CB (1995) [DSM-IV]. Encephale, 21 Spec No 5, 15\u201320."},{"key":"6598_CR34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165\u20131180","journal-title":"J Psychopharmacol"},{"key":"6598_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/17512433.2021.1951473","volume":"14","author":"EE Schenberg","year":"2021","unstructured":"Schenberg EE (2021) Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 14:1317\u20131319","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6598_CR36","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, Mcaleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj 366:l4898","journal-title":"Bmj"},{"key":"6598_CR37","doi-asserted-by":"crossref","unstructured":"Szigeti B, Heifets B (2024) Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging","DOI":"10.1016\/j.bpsc.2024.02.004"},{"key":"6598_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.copsyc.2019.06.036","volume":"32","author":"JM Twenge","year":"2020","unstructured":"Twenge JM (2020) Why increases in adolescent depression may be linked to the technological environment. Curr Opin Psychol 32:89\u201394","journal-title":"Curr Opin Psychol"},{"key":"6598_CR39","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R Von Rotz","year":"2023","unstructured":"Von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jancke L, Preller KH, Vollenweider FX (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 56:101809","journal-title":"EClinicalMedicine"},{"key":"6598_CR40","doi-asserted-by":"publisher","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"PE Wolfson","year":"2020","unstructured":"Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, Carlin SC, Sola E, Hamilton S, Yazar-klosinski B, Emerson A, Mithoefer MC, Doblin R (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep 10:20442","journal-title":"Sci Rep"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06598-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06598-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:05:02Z","timestamp":1716199502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06598-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6598"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06598-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CLH-K received mifepristone and matching placebo for another trial and travel support to CA to present the data at the Corcept Therapeutic Conference (September 2022), holds two patents for the development of negative allosteric modulators targeting the stress system and one patent application on the development of a compound for noradrenergic blockade. All is unrelated to this work. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}